Articles related to CARDIOVASCULAR RISK

“Pelacarsen lowered lipoprotein(a) to less than 50 mg/dL in 98% of participants, but levels rebounded after 16 weeks.”

“This guideline is a tour de force, not just a technical manual. It’s a roadmap for precision, prevention, and equity in hypertension care.” – Ragavendra Baliga, MBBS

In the STEER study, patients using Wegovy® had greater cardiovascular improvements compared to tirzepatide, indicating that the same CV benefit cannot be generalized across other molecules in the GLP-1 or GIP/GLP-1 classes and may come specifically from the semaglutide molecule.

“The main scenario that prompts me to use apoB is when a patient’s traditional lipid panel values are either normal, or even slightly abnormal, but have discrepancy with the quality/quantity of their other comorbid problems.” — Austin Shuxiao, MD

Higher BP at age 7 years was associated with greater risk of premature CVD mortality… demonstrated consistency in the magnitude of the associations within siblings, which mitigates concerns regarding unmeasured confounding.

“Catheter ablation reduced risks for ischemic stroke after 30 days (relative risk 0.63), mortality (RR 0.73), and heart failure hospitalization (RR 0.68), but increased ischemic stroke risk at or before 30 days (RR 6.81).”